This article is more than 5 years old. Information may no longer be current.
Allergan, Mimetogen enter licensing agreement for tavilermide dry eye treatment
Click Here to Manage Email Alerts
Allergan has entered into a licensing agreement with Mimetogen Pharmaceuticals to develop and commercialize tavilermide, a topical formulation of a novel small molecule TrkA agonist for the treatment of dry eye disease, according to an Allergan press release.
Allergan will make an upfront payment of $50 million to Mimetogen and fund the phase 3 development of tavilermide (MIM-D3). Mimetogen will receive potential milestone payments and royalties based on the commercialization of the treatment, the release said.
“Tavilermide brings a novel approach to treating the signs and symptoms of dry eye disease by enhancing the ocular tear film,” David Nicholson, executive vice president and president, Global Brands Research and Development at Allergan, said in the release.
A phase 2 study found that tavilermide 1% significantly improved signs and symptoms when compared with placebo. Two phase 3 clinical studies of tavilermide are underway in the U.S. to evaluate the treatment of dry eye disease.